Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Travere Therapeutics Inc (TVTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/21/2025: TVTX (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
15 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $34.79
Year Target Price $34.79
| 11 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 18.81% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 04/21/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.31B USD | Price to earnings Ratio - | 1Y Target Price 34.27 |
Price to earnings Ratio - | 1Y Target Price 34.27 | ||
Volume (30-day avg) - | Beta 0.74 | 52 Weeks Range 7.72 - 25.29 | Updated Date 06/29/2025 |
52 Weeks Range 7.72 - 25.29 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.78 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -82.88% | Operating Margin (TTM) -52.21% |
Management Effectiveness
Return on Assets (TTM) -23.21% | Return on Equity (TTM) -422.66% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1390756210 | Price to Sales(TTM) 4.8 |
Enterprise Value 1390756210 | Price to Sales(TTM) 4.8 | ||
Enterprise Value to Revenue 5.08 | Enterprise Value to EBITDA -5.67 | Shares Outstanding 88804800 | Shares Floating 79018527 |
Shares Outstanding 88804800 | Shares Floating 79018527 | ||
Percent Insiders 0.75 | Percent Institutions 113.35 |
Analyst Ratings
Rating 4.6 | Target Price 34.79 | Buy 2 | Strong Buy 11 |
Buy 2 | Strong Buy 11 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Travere Therapeutics Inc
Company Overview
History and Background
Travere Therapeutics Inc. (formerly known as Retrophin) was founded in 2011. Initially focused on developing therapies for rare diseases, the company has evolved through acquisitions and internal development. Key milestones include the acquisition of rare disease assets and the commercialization of its lead products. Retrophin changed its name to Travere Therapeutics in 2020.
Core Business Areas
- Rare Kidney Diseases: Travere focuses on the development and commercialization of therapies for rare kidney diseases, including IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS).
- Other Rare Diseases: The company also has interests in treating other rare diseases, though the current portfolio is primarily focused on kidney diseases.
Leadership and Structure
The leadership team includes a CEO, CFO, and other senior executives responsible for research and development, commercial operations, and corporate strategy. The organizational structure is typical of a publicly traded biotechnology company, with functional departments and reporting lines.
Top Products and Market Share
Key Offerings
- Filspari (sparsentan): Filspari is approved for the treatment of IgAN. It has the ability to potentially reduce proteinuria in IgAN patients. The market share is still developing, revenue estimates are $150M - $200M for 2024. Competitors include Calliditas Therapeutics (CALT) with Tarpeyo.
- Cholbam (cholic acid): Cholbam is approved for bile acid synthesis disorders due to single enzyme defects, and for peroxisomal disorders. It has a small market share, generating approximately $30M annually. There are limited direct competitors, making Cholbam a key offering in its niche market.
Market Dynamics
Industry Overview
The pharmaceutical industry, especially in rare diseases, is characterized by high regulatory hurdles, high development costs, and significant market exclusivity upon approval. Innovation and clinical data are vital.
Positioning
Travere Therapeutics is positioned as a company specializing in rare kidney diseases, with a focus on unmet medical needs and orphan drug designations. Its competitive advantages lie in its focused portfolio and market exclusivity.
Total Addressable Market (TAM)
The TAM for IgAN and other rare kidney diseases is estimated to be in the billions of dollars. Travere is positioning itself to capture a significant portion of this market with Filspari and potential future pipeline products.
Upturn SWOT Analysis
Strengths
- Approved products with market exclusivity
- Strong focus on rare kidney diseases
- Experienced leadership team
- Pipeline of potential new therapies
Weaknesses
- Reliance on a limited number of products
- High development costs
- Regulatory risk
- Competition in rare disease space
Opportunities
- Expansion into new rare disease areas
- Acquisition of additional assets
- Partnerships with other pharmaceutical companies
- Positive clinical trial results for pipeline products
Threats
- Competition from other pharmaceutical companies
- Failure of clinical trials
- Regulatory changes
- Pricing pressures
Competitors and Market Share
Key Competitors
- CALT
- GSK
Competitive Landscape
Travere Therapeutics competes with other pharmaceutical companies in the rare disease space. Its competitive advantage lies in its focused portfolio and market exclusivity for certain products. However, competition is increasing as more companies enter the rare disease market.
Major Acquisitions
Bipolaris
- Year: 2014
- Acquisition Price (USD millions): 150
- Strategic Rationale: The acquisition of Bipolaris provided Travere with intellectual property related to certain rare disease therapies.
Growth Trajectory and Initiatives
Historical Growth: Travere's growth has been driven by acquisitions and product launches. The company has shown significant revenue growth in recent years.
Future Projections: Analysts project continued revenue growth for Travere, driven by increased adoption of Filspari and potential new product approvals. Profitability is expected to improve over time.
Recent Initiatives: Recent strategic initiatives include expanding commercial operations for Filspari, advancing pipeline products through clinical trials, and exploring potential acquisitions.
Summary
Travere Therapeutics is a growing pharmaceutical company focused on rare kidney diseases, particularly IgAN. Filspari is showing strong potential, driving revenue growth. The company faces competition and regulatory challenges, but its focused strategy and market exclusivity provide a competitive advantage. Continued clinical development and commercial execution are key to future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Press releases
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Travere Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2012-11-08 | President, CEO & Director Dr. Eric M. Dube Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 385 | Website https://www.travere.com |
Full time employees 385 | Website https://www.travere.com | ||
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.